For Patients

A brighter future for patients

Our mission is to advance medicines that will provide a brighter future for patients with serious conditions that are not fully served by existing treatments.

Our current focus is familial adenomatous polyposis (FAP), type 1 diabetes and primary and metastatic cancers of the brain.

The company’s lead development programme, eRapa™, is being readied for a phase 3 registration study in familial adenomatous polyposis (FAP), a rare and serious condition where the only successful treatment option is bowel resection.

three generations of females